9月3日，亚盛医药盘中上涨5.02%，报34.3港元，成交额5723.52万港元。消息面上，多重利好共振推动股价走强。
近日恰逢世界慢性淋巴细胞白血病日，公司核心产品利生妥（利沙托克拉）作为全球首个获批单药治疗BTK抑制剂经治CLL/SLL患者的Bcl-2抑制剂，获密集报道关注。利生妥已获《CSCO淋巴瘤诊疗指南》I级推荐，并被纳入全国27省194城84个惠民保项目，目前公司正全力推进国家医保谈判。此外，中金近期维持亚盛医药跑赢行业评级，目标价45港元。基本面方面，公司上半年收入3.02亿元人民币，同比增长29.3%，产品销售收入同比增长32.6%，商业化造血能力持续提升，围绕利生妥已布局GLORA等4项全球注册III期临床试验，全球化进程加速。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.